Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,563 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dose D Clear all
Terminated Phase 1Phase 2 Interventional Results available

FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer

NCT01133990
View directory record Official record
Conditions
Colorectal Cancer
Interventions
FOLFIRI, E7820, Bevacizumab
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Denver, Colorado • Berkeley Heights, New Jersey • Mount Holly, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 1, 2026, 10:14 PM EDT
Completed Phase 1 Interventional

Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia

NCT04996160
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Pediatric, Relapsed Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
Palbociclib, Dexamethasone, Bortezomib, Doxorubicin
Drug
Lead sponsor
Tanja Andrea Gruber
Other
Eligibility
Up to 25 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 1, 2026, 10:14 PM EDT
Recruiting Not applicable Interventional

Intrathecal Baclofen and Pediatric Dystonia

NCT06606574
View directory record Official record
Conditions
Dystonic Cerebral Palsy
Interventions
Titration protocol
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 17 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Sep 1, 2026, 10:14 PM EDT
Completed Phase 2 Interventional

Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications

NCT01455090
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
BMS-650032, BMS-790052, BMS-791325, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
26
States / cities
Birmingham, Alabama • Coronado, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Sep 1, 2026, 10:14 PM EDT
Terminated Not applicable Interventional Results available

Vitamin D Deficiency and Atopic Dermatitis

NCT01337635
View directory record Official record
Conditions
Atopic Dermatitis, Vitamin D Deficiency
Interventions
Vitamin D
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Sep 1, 2026, 10:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Whitening Effect of Mineral Sunscreens in Multi-Cultural Skin Tones

NCT05565625
View directory record Official record
Conditions
Sunscreen
Interventions
Sunscreen A, Sunscreen B, Sunscreen C, Sunscreen D, Sunscreen E, Sunscreen F
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Sep 1, 2026, 10:14 PM EDT
Withdrawn Phase 2 Interventional

Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients

NCT02678520
View directory record Official record
Conditions
Prostate Cancer
Interventions
3-D Conformal Radiation Therapy, Intensity Modulated Radiation Therapy, Casodex, Zoladex , Lupron
Radiation · Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fairway, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Sep 1, 2026, 10:14 PM EDT
Completed Phase 1 Interventional

Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer And Lung Dysfunction

NCT00009789
View directory record Official record
Conditions
Lung Cancer
Interventions
accelerated conformational radiotherapy
Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
20
States / cities
Fort Lauderdale, Florida • Hollywood, Florida • Jupiter, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 1, 2026, 10:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm

NCT03531918
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Cladribine, Cytarabine, Gemtuzumab Ozogamicin, Recombinant Granulocyte Colony-Stimulating Factor, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride
Drug · Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 1, 2026, 10:14 PM EDT
Active, not recruiting Phase 2 Interventional

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

NCT06001385
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasm, Lymphoma, Chronic Myelomonocytic Leukemia, Pro-Lymphocytic Leukemia, Myelofibrosis
Interventions
Busulfan, Fludarabine, PBSC Hematopoietic Stem Cell Transplantation (HSCT), Post-Transplant Cyclophosphamide, Mesna, Tacrolimus, Mycophenolate Mofetil, Patient Reported Outcomes, Melphalan, Total-body irradiation, Cyclophosphamide
Drug · Procedure · Other + 1 more
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
32
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 1, 2026, 10:14 PM EDT
Completed Phase 1 Interventional

An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment

NCT03335540
View directory record Official record
Conditions
Advanced Cancer
Interventions
Nivolumab, Relatlimab, Cabiralizumab, Ipilimumab, IDO1 Inhibitor, Radiation Therapy
Biological · Drug · Radiation
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Sep 1, 2026, 10:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

NCT03136185
View directory record Official record
Conditions
Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF), Primary Myelofibrosis (PMF)
Interventions
Bomedemstat
Drug
Lead sponsor
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Sep 1, 2026, 10:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults

NCT01458054
View directory record Official record
Conditions
Hepatitis C
Interventions
Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose), Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 1, 2026, 10:14 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients

NCT00089466
View directory record Official record
Conditions
HIV Infections
Interventions
AMD11070
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
3
States / cities
Birmingham, Alabama • Atlanta, Georgia • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 1, 2026, 10:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia

NCT01243151
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemia
Interventions
PF-04950615 (RN316)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
9
States / cities
Culver City, California • Glendale, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Sep 1, 2026, 10:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants

NCT06895356
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Tavapadon
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Sep 1, 2026, 10:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treatment Study of Vitamin D Deficiency in Adolescents

NCT01784029
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
Vitamin D3
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
13 Years to 20 Years
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Sep 1, 2026, 10:14 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Vitamin D for Painful Nocturnal Leg Cramps

NCT00715429
View directory record Official record
Conditions
Leg Cramps, Nocturnal
Interventions
vitamin d, placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Sep 1, 2026, 10:14 PM EDT
Not yet recruiting Phase 1 Interventional

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

NCT04579523
View directory record Official record
Conditions
Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide, Fludarabine Phosphate, Total-Body Irradiation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, X-Ray Imaging
Procedure · Biological · Drug + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 1, 2026, 10:14 PM EDT
Completed Phase 3 Interventional

Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

NCT00067561
View directory record Official record
Conditions
Irritable Colon, Irritable Bowel Syndrome (IBS)
Interventions
Alosetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
177
States / cities
Birmingham, Alabama • Calera, Alabama • Tuscaloosa, Alabama + 149 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 1, 2026, 10:14 PM EDT
Completed Phase 1 Interventional

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

NCT00258245
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
ascorbic acid, arsenic trioxide, bortezomib, dexamethasone, thalidomide, Aspirin
Dietary Supplement · Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 28, 2013 · Synced Sep 1, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder

NCT00854100
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + placebo, Antidepressant + cariprazine (0.1-0.3 mg/day), Antidepressant + cariprazine (1-2 mg/d)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
41
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Arcadia, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 1, 2026, 10:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants

NCT06877702
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986460
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 1, 2026, 10:14 PM EDT
Completed Not applicable Interventional Results available

The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment

NCT01371877
View directory record Official record
Conditions
Urticaria, Angioedema, Hives, Swelling
Interventions
High Dose Vitamin D3, Low Dose Vitamin D3
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 1, 2026, 10:14 PM EDT